SCHEMBL17388705

SCHEMBL17388705

CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](C(C)C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C

nearest known ligand 0.61

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.57
GPBAR1 Q8TDU6 9/20 0.56
HSD11B1 P28845 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17388709 0.89 NR1H4 (0.52) GPBAR1HSD11B1
SCHEMBL15994309 0.89 NR1H4 (0.52) GPBAR1HSD11B1
SCHEMBL3781851 0.82 GPBAR1 (0.84) GPBAR1
SCHEMBL18799024 0.82 GPBAR1 (0.84) GPBAR1
SCHEMBL12447370 0.82 GPBAR1 (0.62) GPBAR1
SCHEMBL13129193 0.82 GPBAR1 (0.62) GPBAR1
SCHEMBL13165683 0.82 GPBAR1 (0.62) GPBAR1
SCHEMBL13806590 0.82 GPBAR1 (0.62) GPBAR1
SCHEMBL3788023 0.81 GPBAR1 (0.72) GPBAR1
SCHEMBL15362556 0.81 GPBAR1 (0.71) GPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10464963-B2 Compounds from invasive Salvinias and methods of using the same STEPHEN F. AUSTIN STATE UNIVERSITY (US) 2019-11-05 US disclosed
US-20180057524-A1 COMPOUNDS FROM INVASIVE SALVINIAS AND METHODS OF USING THE SAME STEPHEN F. AUSTIN STATE UNIVERSITY 2018-03-01 US disclosed
US-9809615-B2 Anti-cancer compounds from invasive salvinias and methods of treating cancer STEPHEN F. AUSTIN STATE UNIVERSITY (US) 2017-11-07 US disclosed
US-20160002279-A1 COMPOUNDS FROM INVASIVE SALVINIAS AND METHODS OF USING THE SAME STEPHEN F. AUSTIN STATE UNIVERSITY 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10464963-B2 Compounds from invasive Salvinias and methods of using the same MMP8, GUSB, MMP9 PTPN1 4369/4885GPBAR1 2853/4885HSD11B1 1144/4885
US-20180057524-A1 COMPOUNDS FROM INVASIVE SALVINIAS AND METHODS OF USING THE SAME MMP8, GUSB, MMP9 PTPN1 4369/4885GPBAR1 2853/4885HSD11B1 1144/4885
US-20160002279-A1 COMPOUNDS FROM INVASIVE SALVINIAS AND METHODS OF USING THE SAME MMP8, GUSB, MMP9 PTPN1 4369/4885GPBAR1 2853/4885HSD11B1 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.